← Back to Screener
Pliant Therapeutics, Inc. Common Stock (PLRX)
Price$1.30
Favorite Metrics
Price vs S&P 500 (26W)-18.37%
Price vs S&P 500 (4W)-3.48%
Market Capitalization$81.11M
All Metrics
Book Value / Share (Quarterly)$2.95
P/TBV (Annual)2.73x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-2.09
Price vs S&P 500 (YTD)4.73%
Net Profit Margin (TTM)-2871.17%
EPS (TTM)$-3.39
10-Day Avg Trading Volume0.35M
EPS Excl Extra (TTM)$-3.39
EPS (Annual)$-2.43
ROI (Annual)-82.42%
Net Profit Margin (5Y Avg)-2573.80%
Cash / Share (Quarterly)$3.11
ROA (Last FY)-66.31%
EBITD / Share (TTM)$-3.57
ROE (5Y Avg)-54.77%
Operating Margin (TTM)-3156.66%
Cash Flow / Share (Annual)$-2.09
P/B Ratio0.45x
P/B Ratio (Quarterly)0.41x
Net Income / Employee (Annual)$-3
EV / Revenue (TTM)7.09x
ROA (TTM)-55.66%
EPS Incl Extra (Annual)$-2.43
Current Ratio (Annual)12.00x
Quick Ratio (Quarterly)11.79x
3-Month Avg Trading Volume0.98M
52-Week Price Return-7.75%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$8.40
P/S Ratio (Annual)51.33x
Asset Turnover (Annual)0.00x
52-Week High$1.95
Operating Margin (5Y Avg)-2871.54%
EPS Excl Extra (Annual)$-2.43
CapEx CAGR (5Y)-24.55%
Tangible BV CAGR (5Y)147.93%
26-Week Price Return-14.38%
Quick Ratio (Annual)11.79x
13-Week Price Return-1.50%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)12.00x
Enterprise Value$35.663
Asset Turnover (TTM)0.01x
Book Value / Share Growth (5Y)-17.99%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-10211.14%
Cash / Share (Annual)$3.11
3-Month Return Std Dev52.17%
Net Income / Employee (TTM)$-4
ROE (Last FY)-82.42%
EPS Basic Excl Extra (Annual)$-2.43
Receivables Turnover (TTM)1.58x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-3.39
Receivables Turnover (Annual)1.58x
ROI (TTM)-66.33%
P/S Ratio (TTM)16.12x
Pretax Margin (5Y Avg)-2573.80%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$6.40
Price vs S&P 500 (52W)-37.58%
Year-to-Date Return7.38%
5-Day Price Return-2.96%
EPS Normalized (Annual)$-2.43
ROA (5Y Avg)-45.99%
Net Profit Margin (Annual)-10211.14%
Month-to-Date Return3.97%
Cash Flow / Share (TTM)$-2.74
EBITD / Share (Annual)$-2.55
Operating Margin (Annual)-11654.75%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-53.14%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-3.39
P/TBV (Quarterly)1.70x
P/B Ratio (Annual)0.41x
Pretax Margin (TTM)-2871.17%
Book Value / Share (Annual)$2.95
Price vs S&P 500 (13W)-2.19%
Beta1.30x
Revenue / Share (TTM)$0.00
ROE (TTM)-73.45%
52-Week Low$1.09
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
2.58
2.58
2.58
2.55
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
PLRXPliant Therapeutics, Inc. Common Stock | 16.12x | — | — | — | $1.30 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Pliant Therapeutics is a clinical-stage biopharmaceutical company developing oral therapies for fibrotic diseases. Its lead candidate, bexotegrast, is a small-molecule treatment in development for idiopathic pulmonary fibrosis and primary sclerosing cholangitis. The company targets significant unmet needs in fibrosis treatment.